A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors

导出原文传递

翻译打印收藏纠错

作者： Tolcher, Anthony W. ^[1] ; Bendell, Johanna C. ^[2] ; Papadopoulos, Kyriakos P. ^[3] ; Burris, Howard A. ; Patnaik, Amita ; Fairbrother, Wayne J. ; Wong, Harvey ; Budha, Nageshwar ; Darbonne, Walter C. ; Peale, Franklin ; Mamounas, Michael ; Royer-Joo, Stephanie ; Yu, Ron ; Portera, Chia C. ; Infante, Jeffrey R.

作者单位： Genentech Inc, San Francisco, CA 94080 USA ^[1] Sarah Cannon Res Inst, Nashville, TN USA ^[2] START Ctr Canc Care, South Texas Accelerated Res Therapeut, 4383 Med Dr,Suite 4026, San Antonio, TX ^[3]

发布时间 2017-04-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical cancer research

2016年22卷18期

4567-4573页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除